ArticleOncology letters2025

BLID is a drug-responsive target of FOXO3a and multi-omics analysis reveals survival mechanisms and therapeutic vulnerabilities in BLID-deficient breast cancer cells.

Sivaramakrishna Yadavalli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.